Sanofi’s Post

#transcript James McCullough, CEO of Renalytix, is focused on preventive care for those most likely to get chronic kidney disease. Diagnostics and risk assessment of patients earlier in the disease cycle emphasize maintaining kidney health rather than managing complications from late-stage kidney disease and kidney failure. Using a machine-learning algorithm to look at blood-based biomarkers and EMR data, the KidneyIntelX system provides the clinician with a risk score and guidelines for treatment. @Renalytix #KidneyDisease #KidneyHealth #DIgitalHealth #AI #MachineLearning #Diagnostics  renalytix.com https://lnkd.in/gb4jWTyz

🚨 A fascinating scoping review has been produced by the brilliant Pr Raphaèle Seror (MD, PhD) and Yann Nguyen, who aimed to identify outcome domains in primary Sjögren’s disease, conducted along with the OMERACT working group. 🔎 A lot of the work on identifying outcome domains in primary Sjogren’s disease from the scoping review, had been used in the development process of the candidate STAR endpoint (Sjögren's Tool for Assessing Response), the primary objective of NECESSITY Project ☕Take a moment for this interesting and quick read. #Sjogrens #Outcomes #Research #Scoping #Review

🔍 New Publication Alert! Understanding the Real Prevalence of Interstitial Lung Disease in Rheumatoid Arthritis Patients In the realm of rare diseases, accurately estimating prevalence is a significant challenge. Literature suggests a wide prevalence range for interstitial lung disease associated with Rheumatoid Arthritis (RA) - from 1% to 60%. This vast variability poses real-world difficulties in diagnosis, treatment planning, and resource allocation, impacting patient care and research focus. 📊 Our recent study, published in RMD Open, leverages machine learning and big data to shed light on this issue. By analyzing a cohort of 14,000 RA patients, we've derived reliable real-world data, estimating that this condition affects 1 in every 20 patients. This finding narrows the prevalence gap and provides a clearer target for healthcare providers and researchers. This work was made possible through collaboration with esteemed institutions and colleagues, including various Spanish hospitals, the innovative team at SAVANA Med, and the support of Bristol Myers Squibb (BMS) and Sandra Orta. I extend my heartfelt gratitude to @Jose Andres Roman Ivorra, Ignacio H. Medrano and Diego Benavent Nuñez for their significant contributions and unwavering commitment to this project. 📝 Our findings underscore the power of technology in transforming medical research and patient care. Dive into our publication to explore how big data and machine learning are unveiling the real face of rare disease prevalence: https://lnkd.in/dZ-Gdd8n #RheumatoidArthritis #InterstitialLungDisease #MachineLearning #BigData #MedicalResearch #BMSiberia #HealthcareInnovation #SAVANAMed

Predominant diarrheal diseases (CDI, IBD & IBS) could affect over 10% world population, and diagnositic challenges exist. We asked us some key questions - 1) What are gut microbiome differences among those conditions at a population scale? 2) How should we analyze microbiome data that were sequenced across multiple platforms/labs? 3) Given the fact that the high-cost colonoscopy is commonly used to aid clinical diagnosis on these conditions, could we use gut microbiome features for differentiating them? Here are our answers just published in the Journal of Clinical Investigation.

Putting on my mitochondriac hat and reposting for awareness. If you have an interest in mitochondrial diseases or know someone who does, please comment and/or share! Well vetted common data elements are vital for efficient, rigorous, reproducible, and maximally impactful research. Thanks to National Institute of Neurological Disorders and Stroke (NINDS) and M. Carolina M. for advancing this effort! #mitochondria #mitochondrialdisease #commondataelements #rarediseases